Macor et al. tested two types of bispecific antibodies, CD20/CD55 (MB20/55) and CD20/CD59 (MB20/59)—each of them composed by anti-complement regulator antibody (anti-mCRP) and anti-tumour specific antibody, for the treatment of CD20 positive lymphoma [119]. Here, CD59 is linked to neoplasm.